A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause (Starlight 2)
A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant in Japanese Women Experiencing Vasomotor Symptoms (Hot Flashes) Associated With Menopause
Sponsor: Astellas Pharma Inc
Listed as NCT06206408, this PHASE3 trial focuses on Hot Flashes and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 22 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
22 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
▶ Show 17 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — Apr 2025 [monthly]
Recruiting PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beppu-shi, Japan , Bunkyo-ku, Japan , Chiba, Japan , Chita-gun, Japan , Chiyoda-ku, Japan , Chuo-ku, Japan , Fukuoka, Japan , Fukushima, Japan , Funabashi-shi, Japan , Hachioji-shi, Japan and 37 more locations